Camlin Fine Sciences Share News - Latest Updates, Live News & More

Latest news about Camlin Fine Sciences

Camlin Fine Sciences Increases Ownership in Vinpai to 83.82% Through Bond Conversion Jan 09, 2026

Camlin Fine Sciences has increased its ownership in Vinpai to 83.82% by converting convertible bonds into equity shares. This strategic move strengthens the company's control over its subsidiary operations and demonstrates its commitment to consolidating its position within Vinpai's business structure.

Camlin Fine Sciences Increases Vinpai Stake to 83.82% Through Convertible Bond Conversion Jan 09, 2026

Camlin Fine Sciences Vanillin Plant Resolves Technical Issues, Targets Rising Global Demand Jan 09, 2026

Camlin Fine Sciences Responds to BSE Query on Increased Trading Volume Jan 08, 2026

Camlin Fine Sciences Receives GST Demand Order of ₹48.59 Lakh from Tax Authorities Dec 31, 2025

More news about Camlin Fine Sciences

30Nov 25

Camlin Fine Sciences Delays Vinpai Tender Offer Filing Until February 2026

Camlin Fine Sciences has postponed its mandatory tender offer filing for remaining Vinpai shares until end of February 2026, citing delays in Indian regulatory authorizations. The company currently holds 78.68% stake in the French ingredient technology firm, which will increase to 83.82% following automatic conversion of convertible bonds by December 31, 2025.

14Nov 25

Camlin Fine Sciences Reports 8.6% Revenue Growth to Rs. 460 Crores in Q2 FY26, Eyes 4,000 Tons Vanillin Sales Next Year

Camlin Fine Sciences Limited reported Q2 FY2026 revenue of Rs. 460.00 crores, up 8.6% quarter-on-quarter. EBITDA improved to Rs. 33.00 crores with a 7.27% margin. Vanillin sales volume increased by 35%, while the blends business grew by 8%. The company faces challenges from US tariffs and channel inventory in US and European markets. Management expects 4,000 tons of vanillin sales and 20% growth in blends business for the next fiscal year. Strategies include expanding sales force, pursuing inorganic growth, and optimizing capacity utilization.

10Nov 25

Camlin Fine Sciences Reports 41% Growth in Vanillin Segment, Targets Margin Recovery

Camlin Fine Sciences Limited (CFS) reported a 41% year-over-year increase in its vanillin segment. The company is targeting growth in high-value blends and aroma ingredients, expanding its global marketing presence. CFS expects tariff-led margin recovery in H2FY26 and has outlined an acquisition-led growth pipeline. For Q2 FY26, CFS reported a 10.2% increase in revenue to 4,598.30 crore, but faced pressure on margins with EBITDA declining by 35.1% to 334.10 crore. The company's net loss narrowed significantly compared to the previous year.

10Nov 25

Camlin Fine Sciences Shareholders Approve Independent Director Re-appointment

Camlin Fine Sciences successfully completed postal ballot voting for re-appointing Mr. Mahabaleshwar G. Palekar as Independent Director, receiving overwhelming shareholder approval with 99.97% votes in favor. The official results show strong support across all shareholder categories including 100% approval from promoter group.

17Oct 25

Camlin Fine Sciences Issues Corrigendum for Preferential Share Allotment in Vinpai Acquisition

Camlin Fine Sciences Limited (CFSL) has issued a corrigendum to its postal ballot notice regarding a preferential issue of equity shares for acquiring a 78.68% stake in French company Vinpai. CFSL plans to issue 41,06,181 equity shares at ₹247.69 per share, totaling €98.03 million (approx. ₹101.71 crore). Vinpai, an 'ingredien'tech' company, specializes in natural alternatives to chemical additives. The acquisition aims to enhance CFSL's product offerings and market competitiveness. Post-issue, Vinpai shareholders will hold 2.10% of CFSL's expanded share capital, with promoter holding decreasing to 47.08% and public shareholding increasing to 52.92%. CFSL has obtained a valuation report and is allowing members to update their votes until October 29, 2025.

25Sept 25

Camlin Fine Sciences Receives Regulatory Approval for Vinpai Acquisition, Adjusts Timeline

Camlin Fine Sciences has obtained Indian regulatory approvals for its planned acquisition of a majority stake in French company Vinpai S.A. The approval, granted on November 18, 2025, includes an updated timeline for the transaction. Shareholders have approved the deal with 99.99% in favor, at a price of EUR 3.60 per share. The revised schedule sets allotment of consideration shares by November 30, 2025, and filing of the simplified tender offer for mid-December 2025. This represents a delay from the earlier target of September 30, 2025, due to documentation requirements for foreign sellers.

24Sept 25

Camlin Fine Sciences to Consider Preferential Share Allotment for Vinpai Acquisition

Camlin Fine Sciences Limited has scheduled a board meeting on September 29, 2025, to consider issuing equity shares through preferential allotment as part of a share swap to acquire a majority stake in Vinpai S.A. The company has implemented a trading window closure from September 24, 2025, until 48 hours after the board meeting concludes. If approved, the proposal will be subject to shareholder approval via postal ballot. The move aligns with the company's strategic plans disclosed earlier in 2025.

08Aug 25

Camlin Fine Sciences Reports Narrowed Q1 Loss Despite Revenue Dip

Camlin Fine Sciences reported a consolidated net loss of 100 million rupees in Q1, down from 340 million rupees last year, despite revenue falling to 4,236 million rupees from 4,375 million rupees. The Specialty Ingredients (Value-added Blends) segment showed strong growth, while other segments experienced declines. EBITDA decreased to 190 million rupees, with the margin contracting to 4.49%. Regional performance varied, with Mexico and Europe showing growth. The company is focusing on high-value blends and additives, developing new downstream products, and enhancing its naturals and emulsifiers portfolio.

23May 25

Camlin Fine Sciences Reports Improved Q4 EBITDA and Margin, Narrows Losses

Camlin Fine Sciences Ltd. has reported a substantial improvement in its Q4 financial results. The company reduced its net loss to ₹7.00 million from ₹771.00 million year-over-year. Revenue increased by 14.47% to ₹4.35 billion, while EBITDA rose to ₹594.00 million with an improved margin of 13.66%. The company also showed better expense management, with total expenses decreasing by 27.19% quarter-on-quarter.

27Feb 25

Camlin Fine Sciences to Expand Portfolio with Majority Stake Acquisition in Vinpai

Camlin Fine Sciences Ltd (CFSL) plans to acquire a majority stake in Vinpai through a share swap arrangement. The deal values Vinpai shares at €3.60 each. This strategic move aims to expand CFSL's product portfolio and market reach in the specialty chemicals industry. The acquisition is expected to bring portfolio expansion, increased market reach, potential synergies, and enhanced innovation capabilities for CFSL.

25Feb 25

Camlin Fine Sciences to Acquire Up to 100% Stake in French Ingredient-Tech Company Vinpai S.A.

Camlin Fine Sciences Limited (CFS) plans to acquire up to 100% stake in Vinpai S.A., a French ingredient-tech company specializing in natural alternatives to chemical additives. The acquisition involves a multi-step process including a share purchase agreement for a 78.68% stake, a €3.3 million convertible bond investment, and a potential mandatory tender offer for remaining shares. The total acquisition cost could reach €5.96 million. This strategic move aims to expand CFS's product portfolio, access new technologies, and strengthen its position in the food, cosmetics, and nutraceutical industries. Vinpai, founded in 2011, has shown consistent growth with a projected turnover of €9.2 million in 2024.